Krystal Biotech Inc
Company Profile
Business description
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Contact
2100 Wharton Street
Suite 701
PittsburghPA15203
USAT: +1 412 586-5830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
295
Stocks News & Analysis
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
stocks
Market is misinterpreting AI impact on cheap ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,408.70 | 27.40 | -0.29% |
| CAC 40 | 8,624.56 | 65.49 | 0.77% |
| DAX 40 | 25,290.99 | 115.05 | 0.46% |
| Dow JONES (US) | 49,467.74 | 14.41 | -0.03% |
| FTSE 100 | 10,822.36 | 15.95 | 0.15% |
| HKSE | 26,381.02 | 384.70 | -1.44% |
| NASDAQ | 22,788.47 | 363.61 | -1.57% |
| Nikkei 225 | 58,753.39 | 170.27 | 0.29% |
| NZX 50 Index | 13,670.71 | 145.13 | 1.07% |
| S&P 500 | 6,889.85 | 56.28 | -0.81% |
| S&P/ASX 200 | 9,175.30 | 27.60 | -0.30% |
| SSE Composite Index | 4,146.63 | 0.60 | -0.01% |